Abstract: This automobile collision simulation test bogie is equipped with a bogie chassis capable of moving along a rail, and a liquid tank provided to the bogie chassis, having a storage section for storing a test body placed on the bogie chassis, and capable of holding a liquid in said storage section in a state in which the test body is stored therein.

Abstract: The present invention enables testing with high reproducibility under various conditions. This present invention is provided with: a testing platform on which a vehicle to be tested is mounted and which is capable of changing the orientation and the direction of the vehicle to be tested; an environment reproduction mechanism for reproducing the environment around the vehicle to be tested; a running condition reproduction mechanism that moves relatively to the vehicle to be tested and reproduces the running state of the vehicle; and a building that covers the testing platform, the running condition reproduction mechanism, and the environment reproduction mechanism, and that sets the surroundings of the testing platform as an indoor space.

Abstract: The present invention provides: an antibody that has specificity for MUC 4 having a sugar chain structure that is expressed at a high level in cancer cells; a glycopeptide that constitutes an antigen that is suitable for producing this antibody; and a new means and method for the diagnosis, prevention, and/or treatment of cancer by means of the aforementioned antibody. The present invention relates to a monoclonal antibody against a glycopeptide. The glycopeptide comprises a human MUC 4 tandem unit peptide having an amino acid sequence represented by SEQ ID NO: 1, and an O-linked sugar chain. The O-linked sugar chain is N-acetylgalactosamine (GalNAc) and binds to threonine, which is the 8th amino acid of the tandem unit peptide.

Abstract: The present invention provides: an antibody exhibiting specificity for MUC1, the antibody having a glycan structure expressed at high levels in cancer cells; a method for manufacturing this antibody; and a novel means and method for the diagnosis and prevention and/or treatment of cancer using this antibody. The present invention is a monoclonal antibody to human MUC1, wherein the antibody specifically recognizes a glycopeptide having a human MUC1 tandem unit and furthermore having an O-linked glycan core (0(Tn)) in any one of the threonine and serine in the amino acid sequence of this human MUC1 tandem unit. A method for detecting MUC1 in a human body-fluid sample. A kit including this monoclonal antibody. A pharmacological composition for the prevention and/or treatment of a malignant tumor, the pharmacological composition containing this monoclonal antibody as an active ingredient.

Abstract: The present invention provides a method for preparing a sample characterized by binding a substance A containing a hydrazide group to a sugar chain and/or a sugar derivative via hydrazone formation between the hydrazide group of the substance A and the reducing end of the sugar chain and/or the sugar derivative thereby to enable the separation and purification of the sugar chain and/or the sugar derivative for an analytical sample from a biological sample containing the sugar chain and/or the sugar derivative by a simple operation.

Abstract: The present invention provides: an antibody exhibiting specificity for MUC1, the antibody having a glycan structure expressed at high levels in cancer cells; a method for manufacturing this antibody; and a novel means and method for the diagnosis and prevention and/or treatment of cancer using this antibody. The present invention is a monoclonal antibody to human MUC1, wherein the antibody specifically recognizes a glycopeptide having a human MUC1 tandem unit and furthermore having an O-linked glycan core (0(Tn)) in any one of the threonine and serine in the amino acid sequence of this human MUC1 tandem unit. A method for detecting MUC1 in a human body-fluid sample. A kit including this monoclonal antibody. A pharmacological composition for the prevention and/or treatment of a malignant tumor, the pharmacological composition containing this monoclonal antibody as an active ingredient.

Abstract: The present invention provides: an antibody that has specificity for MUC 4 having a sugar chain structure that is expressed at a high level in cancer cells; a glycopeptide that constitutes an antigen that is suitable for producing this antibody; and a new means and method for the diagnosis, prevention, and/or treatment of cancer by means of the aforementioned antibody. The present invention relates to a monoclonal antibody against a glycopeptide. The glycopeptide comprises a human MUC 4 tandem unit peptide having an amino acid sequence represented by SEQ ID NO: 1, and an O-linked sugar chain. The O-linked sugar chain is N-acetylgalactosamine (GalNAc) and binds to threonine, which is the 8th amino acid of the tandem unit peptide.

Abstract: The present invention provides substance which can specifically interact with sugar chains. Further, the present invention provides a method for separating, concentrating, or purifying sugar chains or a sugar chain-containing substance in a sample, comprising the steps of: a) contacting a sugar chain-trapping carrier comprising a substance which can specifically interact with sugar chains with the sample in a fluid phase under conditions that the sugar chain-trapping carrier can react with the sugar chains or sugar chain-containing substance; b) isolating a composite of the sugar chain-trapping carrier and the sugar chains or sugar chain-containing substance from the fluid phase; and c) exposing the composite to the conditions that the interaction between the sugar chain-trapping carrier and the sugar chains or sugar chain-containing substance is at least partially eliminated.

Abstract: The present invention provides a method for preparing a sample characterized by binding a substance A containing a hydrazide group to a sugar chain and/or a sugar derivative via hydrazone formation between the hydrazide group of the substance A and the reducing end of the sugar chain and/or the sugar derivative thereby to enable the separation and purification of the sugar chain and/or the sugar derivative for an analytical sample from a biological sample containing the sugar chain and/or the sugar derivative by a simple operation.

Abstract: The present invention provides substance which can specifically interact with sugar chains. Further, the present invention provides a method for separating, concentrating, or purifying sugar chains or a sugar chain-containing substance in a sample, comprising the steps of: a) contacting a sugar chain-trapping carrier comprising a substance which can specifically interact with sugar chains with the sample in a fluid phase under conditions that the sugar chain-trapping carrier can react with the sugar chains or sugar chain-containing substance; b) isolating a composite of the sugar chain-trapping carrier and the sugar chains or sugar chain-containing substance from the fluid phase; and c) exposing the composite to the conditions that the interaction between the sugar chain-trapping carrier and the sugar chains or sugar chain-containing substance is at least partially eliminated.

Abstract: The present invention provides substance which can specifically interact with sugar chains. Further, the present invention provides a method for separating, concentrating, or purifying sugar chains or a sugar chain-containing substance in a sample, comprising the steps of: a) contacting a sugar chain-trapping carrier comprising a substance which can specifically interact with sugar chains with the sample in a fluid phase under conditions that the sugar chain-trapping carrier can react with the sugar chains or sugar chain-containing substance; b) isolating a composite of the sugar chain-trapping carrier and the sugar chains or sugar chain-containing substance from the fluid phase; and c) exposing the composite to the conditions that the interaction between the sugar chain-trapping carrier and the sugar chains or sugar chain-containing substance is at least partially eliminated.

Abstract: To provide an autoanalyzer for analyzing a sugar chain contained in a biological sample, in particular, serum. Namely, it is intended to provide a method of analyzing a sugar chain in a sample, which comprises the following steps: A) the sugar chain-releasing step of releasing the sugar chain in the sample; B) the detection sample-preparing step of preparing the released sugar chain for detection; and, in the case of conducting mass spectrometry using a plate, C) the step of forming a plate for the mass spectrometry having the captured sugar chain dotted thereon which comprises the step of providing the tagged sugar chain sample solution obtained in the step B) on a collection plate; and, if required, the step of conducting an operation in a solid phase support-enclosed plate to form the plate for mass spectrometry; and D) the step of analyzing the sugar chain to be assayed.

Abstract: The present invention provides a method for preparing a sample characterized by binding a substance A containing a hydrazide group to a sugar chain and/or a sugar derivative via hydrazone formation between the hydrazide group of the substance A and the reducing end of the sugar chain and/or the sugar derivative thereby to enable the separation and purification of the sugar chain and/or the sugar derivative for an analytical sample from a biological sample containing the sugar chain and/or the sugar derivative by a simple operation.

Abstract: The present invention provides a method for preparing a sample characterized by binding a substance A containing a hydrazide group to a sugar chain and/or a sugar derivative via hydrazone formation between the hydrazide group of the substance A and the reducing end of the sugar chain and/or the sugar derivative thereby to enable the separation and purification of the sugar chain and/or the sugar derivative for an analytical sample from a biological sample containing the sugar chain and/or the sugar derivative by a simple operation.

Abstract: The present invention provides a method for preparing a sample characterized by binding a substance A containing a hydrazide group to a sugar chain and/or a sugar derivative via hydrazone formation between the hydrazide group of the substance A and the reducing end of the sugar chain and/or the sugar derivative thereby to enable the separation and purification of the sugar chain and/or the sugar derivative for an analytical sample from a biological sample containing the sugar chain and/or the sugar derivative by a simple operation.

Abstract: After various sugar nucleotide solutions and glycosyltransferases (or primers) have been mixed, they are introduced into a reaction tank (column) with primers (or glycosyltransferases) immobilized thereon. Then solutions coming out of the reaction tank are led to an ultrafiltration column. The oligosaccharide synthesizer according to the present invention is equipped with a flow path for ensuring that glycosyltransferases or primers separated by the ultrafiltration column are returned into a container for storing each solution in a sample injector.

Abstract: A support comprising functional groups supported therein that specifically react with an aldehyde group of a sugar chain, and a polymer particle and a glycochip to which the support is applied, and uses thereof.

Abstract: A method for preparing an analysis sample which involves the sugar chain capture step comprising a reaction of capturing a sugar chain and/or a sugar derivative from a biological sample by using a sugar chain capture agent and the excision step comprising excising a compound containing a moiety capturing the sugar chain and/or the sugar derivative from the sugar chain capture agent after the completion of the sugar chain capture reaction and releasing the compound.

Abstract: An oxylamino group-containing compound represented by the following formula: R1—B-A-B—R2, wherein R1 represents a polymerizable group, R2 represents an oxylamino group-containing group or an oxylamino derivative-containing group, B represents an ester linkage or an amide linkage, and A represents an optionally substituted alkylene group having 2 to 12 carbon atoms.

Abstract: To provide an autoanalyzer for analyzing a sugar chain contained in a biological sample, in particular, serum. Namely, it is intended to provide a method of analyzing a sugar chain in a sample, which comprises the following steps: A) the sugar chain-releasing step of releasing the sugar chain in the sample; B) the detection sample-preparing step of preparing the released sugar chain for detection; and, in the case of conducting mass spectrometry using a plate, C) the step of forming a plate for the mass spectrometry having the captured sugar chain dotted thereon which comprises the step of providing the tagged sugar chain sample solution obtained in the step B) on a collection plate; and, if required, the step of conducting an operation in a solid phase support-enclosed plate to form the plate for mass spectrometry; and D) the step of analyzing the sugar chain to be assayed.